Interferon-induced transmembrane proteins IFITM1 and IFITM3 (IFITM1/3) play a role in both RNA viral restriction and in human cancer progression. Using immunohistochemical staining of FFPE tissue, we identified subgroups of cervical cancer patients where IFITM1/3 protein expression is inversely related to metastasis. Guide RNA-CAS9 methods were used to develop an isogenic IFITM1/IFITM3 double null cervical cancer model in order to define dominant pathways triggered by presence or absence of IFITM1/3 signalling. A pulse SILAC methodology identified IRF1, HLA-B, and ISG15 as the most dominating IFNγ inducible proteins whose synthesis was attenuated in the IFITM1/IFITM3 double-null cells. Conversely, SWATH-IP mass spectrometry of ectopically expressed SBP-tagged IFITM1 identified ISG15 and HLA-B as dominant co-associated proteins. ISG15ylation was attenuated in IFNγ treated IFITM1/IFITM3 double-null cells. Proximity ligation assays indicated that HLA-B can interact with IFITM1/3 proteins in parental SiHa cells. Cell surface expression of HLA-B was attenuated in IFNγ treated IFITM1/IFITM3 double-null cells. SWATH-MS proteomic screens in cells treated with IFITM1-targeted siRNA cells resulted in the attenuation of an interferon regulated protein subpopulation including MHC Class I molecules as well as IFITM3, STAT1, B2M, and ISG15. These data have implications for the function of IFITM1/3 in mediating IFNγ stimulated protein synthesis including ISG15ylation and MHC Class I production in cancer cells. The data together suggest that pro-metastatic growth associated with IFITM1/3 negative cervical cancers relates to attenuated expression of MHC Class I molecules that would support tumor immune escape.

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

University of Edinburgh Institute of Genetics and Molecular Medicine Edinburgh EH4 2XR United Kingdom

University of Edinburgh Institute of Genetics and Molecular Medicine Edinburgh EH4 2XR United Kingdom; Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

University of Edinburgh Institute of Genetics and Molecular Medicine Edinburgh EH4 2XR United Kingdom; Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic; University of Gdansk International Centre for Cancer Vaccine Science Department of Chemistry Gdansk Poland

University of Gdansk International Centre for Cancer Vaccine Science Department of Chemistry Gdansk Poland

See more in PubMed

Takaoka A., Yanai H. Interferon signalling network in innate defence. Cell. Microbiol. 2006;8(6):907–922. PubMed

Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005;5(5):375–386. PubMed

Bekisz J., Schmeisser H., Hernandez J., Goldman N.D., Zoon K.C. Human interferons alpha, beta and omega. Growth Factors. 2004;22(4):243–251. PubMed

Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., Stark G.R. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007;6(12):975–990. PubMed PMC

Darnell J.E., Jr., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421. PubMed

Williams B.R. Transcriptional regulation of interferon-stimulated genes. Eur. J. Biochem. / FEBS. 1991;200(1):1–11. PubMed

Cheon H., Borden E.C., Stark G.R. Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 2014;41(2):156–173. PubMed PMC

Wallace T.A., Martin D.N., Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis. 2011;32(8):1107–1121. PubMed PMC

Khodarev N.N., Roizman B., Weichselbaum R.R. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 2012;18(11):3015–3021. an official journal of the American Association for Cancer Research. PubMed

Weichselbaum R.R., Ishwaran H., Yoon T., Nuyten D.S., Baker S.W., Khodarev N., Su A.W., Shaikh A.Y., Roach P., Kreike B., Roizman B., Bergh J., Pawitan Y., van de Vijver M.J., Minn A.J. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2008;105(47):18490–18495. PubMed PMC

Wu T.H., Schreiber K., Arina A., Khodarev N.N., Efimova E.V., Rowley D.A., Weichselbaum R.R., Schreiber H. Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun. 2011;11:2. PubMed PMC

Borg D., Hedner C., Gaber A., Nodin B., Fristedt R., Jirstrom K., Eberhard J., Johnsson A. Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomark Res. 2016;4:10. PubMed PMC

Gyorffy B., Dietel M., Fekete T., Lage H. A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int. J. Gynecol. Cancer. 2008;18(6):1215–1233. PubMed

Sari I.N., Yang Y.G., Phi L.T., Kim H., Baek M.J., Jeong D., Kwon H.Y. Interferon-induced transmembrane protein 1 (IFITM1) is required for the progression of colorectal cancer. Oncotarget. 2016;7(52):86039–86050. PubMed PMC

Ogony J., Choi H.J., Lui A., Cristofanilli M., Lewis-Wambi J. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast Cancer Res.: BCR. 2016;18(1):25. PubMed PMC

Yu F., Xie D., Ng S.S., Lum C.T., Cai M.Y., Cheung W.K., Kung H.F., Lin G., Wang X., Lin M.C. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett. 2015;368(1):135–143. PubMed

Bailey C.C., Zhong G., Huang I.C., Farzan M. IFITM-family proteins: the cell's first line of antiviral Defense. Annu. Rev. Virol. 2014;1:261–283. PubMed PMC

Jia R., Ding S., Pan Q., Liu S.L., Qiao W., Liang C. The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PLoS One. 2015;10(3) PubMed PMC

Weston S., Czieso S., White I.J., Smith S.E., Kellam P., Marsh M. A membrane topology model for human interferon inducible transmembrane protein 1. PLoS One. 2014;9(8) PubMed PMC

Brass A.L., Huang I.C., Benita Y., John S.P., Krishnan M.N., Feeley E.M., Ryan B.J., Weyer J.L., van der Weyden L., Fikrig E., Adams D.J., Xavier R.J., Farzan M., Elledge S.J. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139(7):1243–1254. PubMed PMC

Amini-Bavil-Olyaee S., Choi Y.J., Lee J.H., Shi M., Huang I.C., Farzan M., Jung J.U. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe. 2013;13(4):452–464. PubMed PMC

Huang I.C., Bailey C.C., Weyer J.L., Radoshitzky S.R., Becker M.M., Chiang J.J., Brass A.L., Ahmed A.A., Chi X., Dong L., Longobardi L.E., Boltz D., Kuhn J.H., Elledge S.J., Bavari S., Denison M.R., Choe H., Farzan M. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7(1) PubMed PMC

Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., Hrstka R., Janotova P., Radina M., Lane D.P., Coates P.J., Vojtesek B. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol. 2005;207(3):251–259. PubMed

Sanjana N.E., Shalem O., Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods. 2014;11(8):783–784. PubMed PMC

Doherty M.K., Beynon R.J. Protein turnover on the scale of the proteome. Expert Rev. Proteomics. 2006;3(1):97–110. PubMed

Doherty M.K., Hammond D.E., Clague M.J., Gaskell S.J., Beynon R.J. Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J. Proteome Res. 2009;8(1):104–112. PubMed

Wang X., Liang Y., Liu L., Shi J., Zhu H.J. Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI) Rapid Commun. Mass Spectrom. 2016;30(5):553–561. PubMed PMC

Kruger N.J. The Bradford method for protein quantitation. Methods Mol. Biol. 1994;32:9–15. PubMed

Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–685. PubMed

Manza L.L., Stamer S.L., Ham A.J., Codreanu S.G., Liebler D.C. Sample preparation and digestion for proteomic analyses using spin filters. Proteomics. 2005;5(7):1742–1745. PubMed

Wisniewski J.R., Zougman A., Nagaraj N., Mann M. Universal sample preparation method for proteome analysis. Nat. Methods. 2009;6(5):359–362. PubMed

Li D., Peng Z., Tang H., Wei P., Kong X., Yan D., Huang F., Li Q., Le X., Li Q., Xie K. KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin. Cancer Res. 2011;17(11):3558–3568. an official journal of the American Association for Cancer Research. PubMed PMC

Seyfried N.T., Huysentruyt L.C., Atwood J.A., 3rd, Xia Q., Seyfried T.N., Orlando R. Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett. 2008;263(2):243–252. PubMed PMC

Yu F., Ng S.S., Chow B.K., Sze J., Lu G., Poon W.S., Kung H.F., Lin M.C. Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J. Neuro-Oncol. 2011;103(2):187–195. PubMed PMC

Yang G., Xu Y., Chen X., Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene. 2007;26(4):594–603. PubMed

Pan Z., Chen S., Pan X., Wang Z., Han H., Zheng W., Wang X., Li F., Qu S., Shao R. Differential gene expression identified in Uigur women cervical squamous cell carcinoma by suppression subtractive hybridization. Neoplasma. 2010;57(2):123–128. PubMed

Zheng W., Zhao Z., Yi X., Zuo Q., Li H., Guo X., Li D., He H., Pan Z., Fan P., Li F., Liao Y., Shao R. Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma. Cancer Cell Int. 2017;17:88. PubMed PMC

Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 1987;61(4):962–971. PubMed PMC

Phelps W.C., Howley P.M. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product. J. Virol. 1987;61(5):1630–1638. PubMed PMC

Bailey C.C., Huang I.C., Kam C., Farzan M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012;8(9) PubMed PMC

Everitt A.R., Clare S., McDonald J.U., Kane L., Harcourt K., Ahras M., Lall A., Hale C., Rodgers A., Young D.B., Haque A., Billker O., Tregoning J.S., Dougan G., Kellam P. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One. 2013;8(11) PubMed PMC

Zhang G., Fenyo D., Neubert T.A. Evaluation of the variation in sample preparation for comparative proteomics using stable isotope labeling by amino acids in cell culture. J. Proteome Res. 2009;8(3):1285–1292. PubMed PMC

Thakur A., Hinnebusch A.G. eIF1 loop 2 interactions with met-tRNAi control the accuracy of start codon selection by the scanning preinitiation complex. Proc. Natl. Acad. Sci. U. S. A. 2018;115(18):E4159–E4168. PubMed PMC

Weibrecht I., Leuchowius K.J., Clausson C.M., Conze T., Jarvius M., Howell W.M., Kamali-Moghaddam M., Soderberg O. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev. Proteomics. 2010;7(3):401–409. PubMed

Raykova D., Koos B., Asplund A., Gelleri M., Ivarsson Y., Danielson U.H., Soderberg O. Let there be light! Proteomes. 2016;4(4) PubMed PMC

Huerfano S., Ryabchenko B., Forstova J. Nucleofection of expression vectors induces a robust interferon response and inhibition of cell proliferation. DNA Cell Biol. 2013;32(8):467–479. PubMed PMC

Li X.Q., Li X.N., Liang J.J., Cai X.B., Tao Q., Li Y.X., Qin Q., Xu S.P., Luo T.R. IRF1 up-regulates isg15 gene expression in dsRNA stimulation or CSFV infection by targeting nucleotides −487 to −325 in the 5′ flanking region. Mol. Immunol. 2018;94:153–165. PubMed

Narayana S.K., Helbig K.J., McCartney E.M., Eyre N.S., Bull R.A., Eltahla A., Lloyd A.R., Beard M.R. The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J. Biol. Chem. 2015;290(43):25946–25959. PubMed PMC

Cheon H., Stark G.R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. U. S. A. 2009;106(23):9373–9378. PubMed PMC

Nan J., Wang Y., Yang J., Stark G.R. IRF9 and unphosphorylated STAT2 cooperate with NF-kappaB to drive IL6 expression. Proc. Natl. Acad. Sci. U. S. A. 2018;115(15):3906–3911. PubMed PMC

Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. PubMed

Lee J., Goh S.H., Song N., Hwang J.A., Nam S., Choi I.J., Shin A., Kim I.H., Ju M.H., Jeong J.S., Lee Y.S. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. Am. J. Pathol. 2012;181(1):43–52. PubMed

McGranahan N., Rosenthal R., Hiley C.T., Rowan A.J., Watkins T.B.K., Wilson G.A., Birkbak N.J., Veeriah S., Van Loo P., Herrero J., Swanton C., Consortium T.R. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6) (1259–1271 e11) PubMed PMC

Ferns D.M., Heeren A.M., Samuels S., Bleeker M.C.G., de Gruijl T.D., Kenter G.G., Jordanova E.S. Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. J. Immunother. Cancer. 2016;4:78. PubMed PMC

Finlan L.E., Nenutil R., Ibbotson S.H., Vojtesek B., Hupp T.R. CK2-site phosphorylation of p53 is induced in DeltaNp63 expressing basal stem cells in UVB irradiated human skin. Cell Cycle. 2006;5(21):2489–2494. PubMed

Park H.J., Kuk I.S., Kim J.H., Kim J.H., Song S.J., Choi B.C., Kim B., Kim N.H., Song H. Characterisation of mouse interferon-induced transmembrane protein-1 gene expression in the mouse uterus during the oestrous cycle and pregnancy. Reprod. Fertil. Dev. 2011;23(6):798–808. PubMed

Warren C.J., Griffin L.M., Little A.S., Huang I.C., Farzan M., Pyeon D. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One. 2014;9(5) PubMed PMC

Wang H.R., Li Y.C., Guo H.Q., Yu L.L., Wu Z., Yin J., Liao G.D., Qu Y.M., Jiang Y., Wang D., Chen W. A cocktail of p16(INK4a) and Ki-67, p16(INK4a) and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening. Oncotarget. 2017;8(48):83890–83899. PubMed PMC

Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., van der Burg S.H., Melief C.J. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009;361(19):1838–1847. PubMed

Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer. 2008;8(5):351–360. PubMed

Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., van der Burg S.H., Melief C.J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002;169(1):350–358. PubMed

Kooi S., Zhang H.Z., Patenia R., Edwards C.L., Platsoucas C.D., Freedman R.S. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell. Immunol. 1996;174(2):116–128. PubMed

Farshchian M., Matin M.M., Armant O., Geerts D., Dastpak M., Nakhaei-Rad S., Tajeran M., Jebelli A., Shahriyari M., Bahrami M., Fallah A., Yaghoobi V., Mirahmadi M., Abbaszadegan M.R., Bahrami A.R. Suppression of dsRNA response genes and innate immunity following Oct4, Stella, and Nanos2 overexpression in mouse embryonic fibroblasts. Cytokine. 2018;106:1–11. PubMed

Chesarino N.M., McMichael T.M., Yount J.S. E3 ubiquitin ligase NEDD4 promotes influenza virus infection by decreasing levels of the antiviral protein IFITM3. PLoS Pathog. 2015;11(8) PubMed PMC

Yount J.S., Karssemeijer R.A., Hang H.C. S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J. Biol. Chem. 2012;287(23):19631–19641. PubMed PMC

Bassani-Sternberg M., Braunlein E., Klar R., Engleitner T., Sinitcyn P., Audehm S., Straub M., Weber J., Slotta-Huspenina J., Specht K., Martignoni M.E., Werner A., Hein R., H Busch D., Peschel C., Rad R., Cox J., Mann M., Krackhardt A.M. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 2016;7:13404. PubMed PMC

Burks J., Reed R.E., Desai S.D. Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective. Oncotarget. 2015;6(9):7221–7231. PubMed PMC

Dos Santos P.F., Mansur D.S. Beyond ISGlylation: functions of free intracellular and extracellular ISG15. J. Interf. Cytokine Res. 2017;37(6):246–253. PubMed

Okumura A., Lu G., Pitha-Rowe I., Pitha P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. U. S. A. 2006;103(5):1440–1445. PubMed PMC

van Montfoort N., van der Aa E., Woltman A.M. Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front. Immunol. 2014;5:182. PubMed PMC

Wahl A., Schafer F., Bardet W., Buchli R., Air G.M., Hildebrand W.H. HLA class I molecules consistently present internal influenza epitopes. Proc. Natl. Acad. Sci. U. S. A. 2009;106(2):540–545. PubMed PMC

Worrall E.G., Wawrzynow B., Worrall L., Walkinshaw M., Ball K.L., Hupp T.R. Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J. Chem. Biol. 2009;2(3):113–129. PubMed PMC

IFITM1 as a modulator of surfaceome dynamics and aggressive phenotype in cervical cancer cells

Biochemical evidence for conformational variants in the anti-viral and pro-metastatic protein IFITM1

IFITM protein regulation and functions: Far beyond the fight against viruses

Identification of novel interferon responsive protein partners of human leukocyte antigen A (HLA-A) using cross-linking mass spectrometry (CLMS) approach

Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer

The Role of IFITM Proteins in Tick-Borne Encephalitis Virus Infection